Investor Relations

Latest Financial Results

Stock Information

Aurinia Pharmaceuticals Inc.
Nasdaq: AUPH Symbol
Price
Change
Volume
Day Range
52 Wk Range

Company Overview

Aurinia is a late clinical stage biopharmaceutical company focused on developing and commercializing therapies in disease areas of high unmet medical need. We are currently developing voclosporin, an investigational drug, for the treatment of lupus nephritis (LN) and focal segmental glomerularsclerosis (FSGS). Additionally, we are advancing voclosporin ophthalmic solution (VOS), a topical formulation, for the treatment of dry eye syndrome (DES).

view management team  view board of directors

Contact Information

Investor Relations

Glenn Schulman, PharmD, MPH
Senior Vice President, Corporate Communications and Investor Relations
IR@auriniapharma.com

Transfer Agent

Computershare Trust Company of Canada
Shareholder Services Dept.
100 University Avenue
9th Floor
Toronto, ON M5J 2Y1
Canada
T: +1-514-982-7555
service@computershare.com
www.computershare.com